Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 4/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23182722 | 0.80 | HRH3 (0.34) | HRH3HRH4CPN1CPB2KMT2A | |
| SCHEMBL21400297 | 0.79 | HRH3 (0.33) | HRH3HRH4CPN1CPB2KMT2A | |
| SCHEMBL7755214 | 0.78 | — | — | |
| SCHEMBL7755205 | 0.78 | — | — | |
| SCHEMBL9112176 | 0.77 | HRH3 (0.37) | HRH3HRH4CPN1CPB2KMT2A | |
| SCHEMBL11923025 | 0.77 | KMT2A (0.37) | HRH3HRH4CPN1CPB2KMT2A | |
| SCHEMBL6022128 | 0.76 | — | — | |
| SCHEMBL7758392 | 0.76 | ADH1B (0.32) | — | |
| SCHEMBL7759079 | 0.76 | ADH1B (0.32) | — | |
| SCHEMBL7758393 | 0.76 | ADH1B (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |